Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders

American Journal of Hematology

Volumn 79, Issue 3, 2005, Pages 211-215

  Komrokji, Rami S ^a,b   Oliva, Jamie L ^c   Zand, Martin ^d   Felgar, Raymond ^d   Abboud, Camille N ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF NURSING   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Autologous stem cell transplantation; Mini BEAM; Post transplant lymphoproliferative disorders

Indexed keywords

ANTIVIRUS AGENT; CARBOPLATIN; CARMUSTINE; CYTARABINE; ETOPOSIDE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHYLPREDNISOLONE SODIUM SUCCINATE; OKT 3; ORTHOCLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ALLOGRAFT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MALE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MELPHALAN; MIDDLE AGED; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTS;

EID: 22044457158     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20334     Document Type: Article

References (20)

1. Harris NL, Swerdlow S, Frizzera G, Knowles DM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues, Lyon, France: LARC; 2001. p 264-271.
2. Allen U, Hebert D, Moore D, Dror Y, Wasfy S. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr Transplant 2001;5(3):198-203.
3. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995;59(2):240-244.
4. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71(8):1076-1088.
5. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86(9):3333-3340.
6. Morrison V, Bartlett N, Dunn DL, Peterson BA. Rituximab therapy for post-transplant lymphoproliferative disorders (PTLD): preliminary outcome results (abstract). Proc Am Soc Clin Oncol 2001;20:295a (abstr 1177).
7. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001;115(1):112-118.
8. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000;18(21):3622-3632.
9. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68(10): 1517-1525.
10. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998;66(12):1770-1779.
11. Velasquez WS, McLaughlm P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12(6):1169-1176.
12. Girouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997;8(7):675-680.
13. Garcia VD, Bonamigo Filho JL, Neumann J, et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003;16(3):202-206.
14. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19(56):6680-6686.
15. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62(21):6141-6145.
16. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protectmg doses. Transplantation 2003;75(10): 1710-1717.
17. Majewski M, Korecka M, Kossev P, et al. The immunosuppres-sive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000;97(8): 4285-4290.
18. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31(5):335-340.
19. Beatty PR, Krams SM, Esquivel CO, Martinez OM. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation 1998;65(9): 1248-1255.
20. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003;63(15):4472-4480.